Early Financial Outcomes of Physician Modified Endograft Programs Are Dictated by Device Cost.

Autor: Kedwai BJ; Division of Vascular Surgery, Department of Surgery, University of Rochester Medical Center, Rochester, New York., Geiger JT; Division of Vascular Surgery, Department of Surgery, University of Rochester Medical Center, Rochester, New York., Lehane DJ; Division of Vascular Surgery, Department of Surgery, University of Rochester Medical Center, Rochester, New York., Newhall KA; Division of Vascular Surgery, Department of Surgery, University of Rochester Medical Center, Rochester, New York., Pitcher GS; Division of Vascular Surgery, Department of Surgery, University of Rochester Medical Center, Rochester, New York., Stoner MC; Division of Vascular Surgery, Department of Surgery, University of Rochester Medical Center, Rochester, New York., Mix DS; Division of Vascular Surgery, Department of Surgery, University of Rochester Medical Center, Rochester, New York. Electronic address: dmix@urmc.rochester.edu.
Jazyk: angličtina
Zdroj: The Journal of surgical research [J Surg Res] 2024 Jul; Vol. 299, pp. 17-25. Date of Electronic Publication: 2024 Apr 29.
DOI: 10.1016/j.jss.2024.04.003
Abstrakt: Introduction: Physician-modified endografts (PMEGs) have been used for repair of thoracoabdominal aortic aneurysms (TAAAs) for 2 decades with good outcomes but limited financial data. This study compared the financial and clinical outcomes of PMEGs to the Cook Zenith-Fenestrated (ZFEN) graft and open surgical repair (OSR).
Methods: A retrospective review of financial and clinical data was performed for all patients who underwent endovascular or OSR of juxtarenal aortic aneurysms and TAAAs from January 2018 to December 2022 at an academic medical center. Clinical presentation, demographics, operative details, and outcomes were reviewed. Financial data was obtained through the institution's finance department. The primary end point was contribution margin (CM).
Results: Thirty patients met inclusion criteria, consisting of twelve PMEG, seven ZFEN, and eleven open repairs. PMEG repairs had a total CM of -$110,000 compared to $18,000 for ZFEN and $290,000 for OSR. Aortic and branch artery implants were major cost-drivers for endovascular procedures. Extent II TAAA repairs were the costliest PMEG procedure, with a total device cost of $59,000 per case. PMEG repairs had 30-d and 1-y mortality rates of 8.3% which was not significantly different from ZFEN (0.0%, P = 0.46; 0.0%, P = 0.46) or OSR (9.1%, P = 0.95; 18%, P = 0.51). Average intensive care unit and hospital stay after PMEG repairs were comparable to ZFEN and shorter than OSR.
Conclusions: Our study suggests that PMEG repairs yield a negative CM. To make these cases financially viable for hospital systems, device costs will need to be reduced or reimbursement rates increased by approximately $8800.
(Copyright © 2024 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: